JPMorgan placed Syndax on “Positive Catalyst Watch” ahead of the Q4 revumenib events and keeps an Overweight rating on the shares after speaking with management. The firm continues to see the shares “grinding into” the high-$20s to low-$30s on monotherapy revumenib updates alone, with combo updates as “another upside lever.” The analyst’s Overweight rating is based on the long-term potential for revumenib and axatilimab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX: